๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 40 Guangzhou 36 Hangzhou 28 Chengdu 27 Shanghai 23
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing40 Guangzhou36 Hangzhou28 Chengdu27 Shanghai23
All 52 locations
Target enrolment
to

Trials with a site in Shanghai

23 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer
NCT07692204Gastric Cancer, Oesophageal Carcinoma
Sanofi
Phase 2
30
Shanghai
2026-07-01
Recruiting
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
NCT07412470Kidney Transplant Rejection
Sanofi
Phase 2/3
526
Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanning, Shanghai
2026-03-13
Recruiting
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07225569Hidradenitis Suppurativa
Sanofi
Phase 2
144
Beijing, Changsha, Shanghai, Wuhan
2025-12-29
Recruiting
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
NCT07116031Chronic Graft Versus Host Disease
Sanofi
Phase 2
37
Beijing, Shanghai, Shenzhen, Suzhou
2025-12-02
Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
NCT07170917Hidradenitis Suppurativa
Sanofi
Phase 2
208
Chengdu, Guangzhou, Shanghai, รœrรผmqi
2025-11-06
Recruiting
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
NCT06975722Ulcerative Colitis
Sanofi
Phase 2
99
Huizhou, Guangzhou, Nanjing, Suzhou, Wuxi, Shanghai, Hangzhou, Ningbo
2025-07-07
Recruiting
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
NCT06958536Crohn's Disease
Sanofi
Phase 2
99
Changsha, Changzhou, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang
2025-06-03
By invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic
Sanofi
Phase 3
300
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Wuhan
2025-04-01
Active, closed
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
NCT06867094Colitis Ulcerative
Sanofi
Phase 2
204
Guangzhou, Hangzhou, Huizhou, Jiazhuang, Linhai, Luoyang, Shanghai, Wuhan
2025-03-28
Recruiting
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
NCT06500702Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
Sanofi
Phase 2
84
Beijing, Chengdu, Shanghai
2024-12-19
Active, closed
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
NCT06637631Crohn's Disease
Sanofi
Phase 2
260
Changzhou, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Nanchang, Shanghai
2024-12-10
Active, closed
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
NCT05991323Prurigo Nodularis
Sanofi
Observational
100
Guangzhou, Xi'an, Jinan, Hangzhou, Wenzhou, Beijing, Shanghai, Shenzhen
2023-12-12
Recruiting
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
NCT06082037Lung Transplant Rejection
Sanofi
Phase 3
180
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wuxi
2023-10-10
Active, closed
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
NCT05588843Colitis Ulcerative
Sanofi
Phase 2
187
Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Shenyang
2022-11-25
Active, closed
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
NCT05280548Fabry Disease
Sanofi
Phase 3
104
Beijing, Chengdu, Guangzhou, Shanghai
2022-05-03
Active, closed
Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3
NCT05222906Gaucher's Disease Type III
Sanofi
Phase 3
43
Taipei, Beijing, Guangzhou, Shanghai
2022-04-18
Active, closed
A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants โ‰ฅ16 Years of Age With Fabry Disease
NCT05206773Fabry Disease
Sanofi
Phase 3
122
Beijing, Shanghai, Taiyuan, Zhengzhou
2022-03-11
Recruiting
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
NCT05263206Pruritus
Sanofi
Phase 3
284
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Shanghai, Suzhou, Wuhan
2022-02-15
Active, closed
Clinical Study for Treatment-naรฏve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa
NCT04910776Glycogen Storage Disease Type II
Sanofi
Phase 3
17
Qingdao, Shanghai
2021-09-01
Active, closed
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
NCT04270409Plasma Cell Myeloma
Sanofi
Phase 3
337
Hangzhou, Nanchang, Shanghai, Shenyang, Tianjin
2020-06-16
Active, closed
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
NCT03687359Dermatitis Atopic
Sanofi
Observational
1,860
Beijing, Changsha, Chongqing, Guangzhou, Harbin, Shanghai, Shenzhen, Suzhou
2019-08-15
Active, closed
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
NCT03319667Plasma Cell Myeloma
Sanofi
Phase 3
475
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang
2017-12-07
Rows per page Showing 1–23 of 23
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 23 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

10 of the 23 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 12 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 23 studies
PhaseStudiesRecruitingShare
Phase 210743.5%
Phase 310243.5%
Observational208.7%
Phase 2/3114.3%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
Sanofi2310
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.